1. Cell Cycle/DNA Damage
    Cytoskeleton
    Antibody-drug Conjugate/ADC Related
  2. Microtubule/Tubulin
    ADC Cytotoxin

Monomethyl auristatin E (Synonyms: Vedotin; MMAE)

Cat. No.: HY-15162 Purity: 99.94%
Handling Instructions

Monomethyl auristatin E (MMAE) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.

For research use only. We do not sell to patients.

Monomethyl auristatin E Chemical Structure

Monomethyl auristatin E Chemical Structure

CAS No. : 474645-27-7

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 190 In-stock
Estimated Time of Arrival: December 31
1 mg USD 72 In-stock
Estimated Time of Arrival: December 31
5 mg USD 120 In-stock
Estimated Time of Arrival: December 31
10 mg USD 180 In-stock
Estimated Time of Arrival: December 31
50 mg USD 480 In-stock
Estimated Time of Arrival: December 31
100 mg USD 850 In-stock
Estimated Time of Arrival: December 31
500 mg USD 1920 In-stock
Estimated Time of Arrival: December 31
1 g USD 3240 In-stock
Estimated Time of Arrival: December 31
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Monomethyl auristatin E:

Top Publications Citing Use of Products

    Monomethyl auristatin E purchased from MCE. Usage Cited in: Sci Rep. 2016 Apr 21;6:24954.

    LC-MS/MS analysis quantified the MMAE concentration in the tumors 3, 24, and 72 h after the administration of MMAE alone. The contents of MMAE in the tumor tissues 3, 24, and 72 h after administration are 1155 ± 609, 736 ± 319, and 413 ± 88 fmol/g (mean ± SD, N = 5 for each group), respectively.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Monomethyl auristatin E (MMAE) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.

    IC50 & Target

    Microtubule[1]

    In Vitro

    Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[1]. MMAE sensitizes colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells[2].

    In Vivo

    Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolongs tumor regression in xenograft models[2].

    Clinical Trial
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 48 mg/mL (66.85 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.3928 mL 6.9640 mL 13.9280 mL
    5 mM 0.2786 mL 1.3928 mL 2.7856 mL
    10 mM 0.1393 mL 0.6964 mL 1.3928 mL
    *Please refer to the solubility information to select the appropriate solvent.
    References
    Cell Assay
    [2]

    Monomethyl auristatin E (MMAE, 5 nM) and ionizing radiation (IR) treated cells are harvested and lysed in RIPA buffer with protease and phosphatase inhibitors. Thirty μg of lysate undergo electrophoresis using 4-12% Bis-Tris gels, transferred to PVDF membranes and incubated with indicated primary antibodies. Blots are developed by ECL.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [2]

    Mice[2]
    6-8 week old female athymic nu/nu mice are injected subcutaneously into thighs with 5×106 HCT-116 or PANC-1 cells in a 1:1 Matrigel and PBS solution. Mice are treated with IR or intravenous (IV) injection of ACPP-cRGD-MMAE (6 nmoles/day, 18 nmoles total, i.v.), tumor tissue is harvested, formalin fixed and paraffin embedded followed by staining with indicated antibodies. The primary antibody is used at a 1:250 dilution and is visualized using DAB as a chromagen with the UltraMap system.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    717.98

    Formula

    C₃₉H₆₇N₅O₇

    CAS No.

    474645-27-7

    SMILES
    Storage

    4°C, stored under nitrogen

    Shipping

    Room temperature in continental US; may vary elsewhere

    Purity: 99.94%

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country or Region *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Monomethyl auristatin E
    Cat. No.:
    HY-15162
    Quantity:

    Monomethyl auristatin E

    Cat. No.: HY-15162